Hangzhou Yirui Pharmaceutical Technology Co., Ltd

This Phase 1 trial tests the safety and tolerability of a new oral drug called YR011 in 64 healthy volunteers. The drug blocks a potassium channel involved in immune cell activity. Participants receive either YR011 or a placebo in single or multiple doses. The study aims to find …